AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cantharidin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5743 | 56-25-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of cantharidin in the treatment of molluscum contagiosum is unknown.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,STK33,SYK,TEK | 24 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 21, 2023 | FDA | VERRICA PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site vesicles | 144.62 | 135.77 | 16 | 34 | 1501 | 90626896 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site vesicles | 186.39 | 142.83 | 20 | 37 | 1544 | 110587698 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D007509 | Irritants |
| CHEBI has role | CHEBI:24527 | herbicide |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:37153 | EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection caused by Molluscum contagiosum | indication | 40070004 | DOID:8867 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | 11052064 | May 28, 2035 | TOPICAL DELIVERY OF A CANTHARIDIN FORMULATION TO ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR TREATING MOLLUSCUM CONTAGIOSUM |
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | 11052064 | May 28, 2035 | TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER |
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | 11147790 | Aug. 22, 2038 | TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER |
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | 11147790 | Aug. 22, 2038 | TOPICAL TREATMENT OF SKIN LESIONS CAUSED BY AN INFECTION WITH MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER |
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | 12233042 | Aug. 22, 2038 | TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.7% | YCANTH | VERRICA PHARMS | N212905 | July 21, 2023 | RX | SOLUTION | TOPICAL | July 21, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Serine/threonine-protein phosphatase PP1-alpha catalytic subunit | Enzyme | INHIBITOR | IC50 | 6.80 | IUPHAR | ||||
| Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform | Enzyme | INHIBITOR | IC50 | 6.70 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| CHEMBL48449 | ChEMBL_ID |
| 13081 | IUPHAR_LIGAND_ID |
| DB12328 | DRUGBANK_ID |
| 437975006 | SNOMEDCT_US |
| 86218002 | SNOMEDCT_US |
| 4019021 | VANDF |
| C0006886 | UMLSCUI |
| D002193 | MESH_DESCRIPTOR_UI |
| 11470 | INN_ID |
| 5944 | PUBCHEM_CID |
| 11889 | MMSL |
| 369647 | MMSL |
| NOCODE | MMSL |
| 001989 | NDDF |
| D11745 | KEGG_DRUG |
| IGL471WQ8P | UNII |
| 1984 | RXNORM |
| IGL471WQ8P | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| YCANTH | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71349-070 | SOLUTION | 3.20 mg | TOPICAL | NDA | 27 sections |
| YCANTH | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71349-999 | SOLUTION | 3.20 mg | TOPICAL | NDA | 27 sections |
| CANTHARIDIN 0.7% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72934-9035 | LIQUID | 0.70 g | TOPICAL | unapproved drug other | 4 sections |
| CANTHARIDIN 1% / PODOPHYLLUM RESIN 5% / SALICYLIC ACID 30% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-9036 | LIQUID | 1 g | TOPICAL | unapproved drug other | 4 sections |